Clinical data | |
---|---|
Pronunciation | /daɪˌhaɪdroʊ.ɜːrˈɡɒtəmiːn/ dy-HY-droh-ur-GOT-ə-meen |
Trade names | D.H.E. 45, Migranal, Trudhesa, others |
Other names | DHE; (5'α)-9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-ergotaman-3',6',18-trione |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603022 |
License data |
|
Routes of administration | Nasal, Subcutaneous, Intramuscular, Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 32% (nasal spray) |
Elimination half-life | 9 hours |
Excretion | Bile |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.007.386 |
Chemical and physical data | |
Formula | C33H37N5O5 |
Molar mass | 583.689 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Dihydroergotamine (DHE), sold under the brand names D.H.E. 45 and Migranal among others, is an ergot alkaloid used to treat migraines.[7] It is a derivative of ergotamine. It is administered as a nasal spray or injection and has an efficacy similar to that of sumatriptan. Nausea is a common side effect.[8]
It has similar actions to the triptans, acting as an agonist to the serotonin receptors and causing vasoconstriction of the intracranial blood vessels, but also interacts centrally with dopamine and adrenergic receptors. It can be used to treat acute intractable headache or withdrawal from analgesics.